Compare Citius Pharmaceuticals Inc (CTXR) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs LyondellBasell Industries NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while LyondellBasell Industries NV trades at $60.2 (market cap $19.49B). The key difference: LyondellBasell Industries NV is far larger — about 1431× Citius Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and LyondellBasell Industries NV for 87 Days on average.
| CTXR | LYB | |
|---|---|---|
Market Cap | $13.62M | $19.49B |
Volume | 132,438 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $82.38 |
52-Week Low | $0.48 | $42.28 |
Typical Hold Time | 16 Days | 87 Days |
Enterprise Value | $3.79M | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings show volatility, with a Q2 2026 beat but a net loss for 2025. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, though 2026 projects a slight recovery. The stock offers a dividend, but news highlights concerns over dividend sustainability amid sector challenges.
Outlook is cautious; analyst consensus is split with a $69.38 price target suggesting upside, but profitability metrics are weak. Key risks include persistent negative margins, high debt, and chemical sector cyclicality. Investment opportunity hinges on operational turnaround and market recovery, but near-term headwinds prevail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
